{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:46:25Z","timestamp":1791013585273,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s00520-011-1336-0","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T05:03:41Z","timestamp":1323320621000},"page":"877-881","source":"Crossref","is-referenced-by-count":52,"title":["Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients"],"prefix":"10.1007","volume":"20","author":[{"given":"C. M. L.","family":"Driessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M. E.","family":"de Kleine-Bolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J. J. M.","family":"Vingerhoets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,9]]},"reference":[{"key":"1336_CR1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF01213547","volume":"122","author":"M Markman","year":"1996","unstructured":"Markman M (1996) Chemotherapy-associated neurotoxicity: an important side-effect impacting on quality, rather than quantity of life. J Cancer Res Clin Oncol 122:511\u2013512","journal-title":"J Cancer Res Clin Oncol"},{"key":"1336_CR2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1525-1438.2003.13603.x","volume":"13","author":"EA Calhoun","year":"2003","unstructured":"Calhoun EA, Welshman EE, Chang CH, Lurain LR, Fishman DA, Hunt TL, Cella D (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynaecologic Oncologic Group-Neurotoxicity (FACT\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741\u2013748","journal-title":"Int J Gynecol Cancer"},{"key":"1336_CR3","first-page":"W1","volume":"4","author":"JA Kopec","year":"2006","unstructured":"Kopec JA, Land SR, Cecchini RS, Ganz PA, Cella D, Costantino JP, Wieand S et al (2006) Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol 4:W1\u2013W8","journal-title":"J Support Oncol"},{"key":"1336_CR4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1188\/04.ONF.615-623","volume":"31","author":"L Almadrones","year":"2004","unstructured":"Almadrones L, Deborah B, Guire M, Walczak J, Colleen M, Tian C (2004) Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology study group. Oncol Nurs Forum 31:615\u2013623","journal-title":"Oncol Nurs Forum"},{"key":"1336_CR5","first-page":"838","volume":"67","author":"TJ Postma","year":"1999","unstructured":"Postma TJ, Heimans JJ, Aaronson NK, Grant R, Huddart R, Maher J, Hildehrand JG et al (1999) The impact of chemotherapy induced peripheral neuropathy on quality of life. J Neurol Neurosurg Psychiatry 67:838","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1336_CR6","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2165\/00003495-200363150-00003","volume":"63","author":"CP Verstappen","year":"2003","unstructured":"Verstappen CP, Heimans JJ, Hoekman K (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63:1549\u20131563","journal-title":"Drugs"},{"key":"1336_CR7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1023\/A:1008345613594","volume":"11","author":"TJ Postma","year":"2000","unstructured":"Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509\u2013513","journal-title":"Ann Oncol"},{"key":"1336_CR8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00007853","volume":"249","author":"S Quasthoff","year":"2002","unstructured":"Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9\u201317","journal-title":"J Neurol"},{"key":"1336_CR9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1081\/CNV-120018236","volume":"21","author":"C Visovsky","year":"2003","unstructured":"Visovsky C (2003) Chemotherapy-induced peripheral neuropathy. Cancer Invest 21:439\u2013451","journal-title":"Cancer Invest"},{"key":"1336_CR10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3816\/CCC.2005.s.006","volume":"5","author":"A Grothey","year":"2005","unstructured":"Grothey A (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorect Cancer 5:38\u201346","journal-title":"Clin Colorect Cancer"},{"key":"1336_CR11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00001813-200307000-00006","volume":"14","author":"JP Durand","year":"2003","unstructured":"Durand JP, Brezault C, Goldwasser F (2003) Protection against oxaliplatin acute neurosensory toxicity by venlafaxine (effexor). Anti-Cancer Drugs 14:423\u2013425","journal-title":"Anti-Cancer Drugs"},{"key":"1336_CR12","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-03-0666","volume":"10","author":"L Gamelin","year":"2004","unstructured":"Gamelin L, Bisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluoroucil and Leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055\u20134061","journal-title":"Clin Cancer Res"},{"key":"1336_CR13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00001813-200311000-00003","volume":"14","author":"S Mielke","year":"2003","unstructured":"Mielke S, Mross K, Gerds TA, Schmitdt A, Wasch R, Berger DP, Lange W et al (2003) Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3\u00a0h. Anti Cancer Drugs 14:785\u2013792","journal-title":"Anti Cancer Drugs"},{"key":"1336_CR14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0162-0134(99)00135-X","volume":"77","author":"D Screnci","year":"1999","unstructured":"Screnci D, Mc Keage MJ (1999) Platinum neurotoxicity: clinical profiles, experimental models and neuroprotectieve approaches. J Inorg Biochem 77:105\u2013110","journal-title":"J Inorg Biochem"},{"key":"1336_CR15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/sonc.2002.35525","volume":"29","author":"E Gamelin","year":"2002","unstructured":"Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Seminars Oncol 29:21\u201333","journal-title":"Seminars Oncol"},{"key":"1336_CR16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2407-5-116","volume":"5","author":"GD Leonard","year":"2005","unstructured":"Leonard GD, Wright MA, Quinn MG (2005) Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 5:116\u2013125","journal-title":"BMC Cancer"},{"key":"1336_CR17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1525-1438.2007.00794.x","volume":"17","author":"HQ Huang","year":"2007","unstructured":"Huang HQ, Brady MF, Cella D, Fleming G (2007) Validation and reduction of FACT\/GOG-Ntx subscale for platinum\/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17:387\u2013393","journal-title":"Int J Gynecol Cancer"},{"key":"1336_CR18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207\u2013214","journal-title":"Cancer"},{"key":"1336_CR19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-011-1336-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T10:59:32Z","timestamp":1497956372000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-011-1336-0"}},"subtitle":["The introduction of a new measure"],"short-title":[],"issued":{"date-parts":[[2011,12,9]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1007\/s00520-011-1336-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,9]]}}}